Arrowhead Pharmaceuticals (ARWR) analyst forecast and price target
Analyst forecast
Consensus of 14 analyst ratings
Based on 9 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | $100.00 | Aug 31, 2026 |
| Chardan Capital | Maintained | Buy | $115.00 | Aug 31, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $120.00 from $115.00 | Aug 6, 2026 |
| B. Riley Securities | Maintained | Buy | $123.00 from $101.00 | Jul 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $115.00 from $100.00 | Jul 27, 2026 |
| Piper Sandler | Maintained | Overweight | $126.00 from $110.00 | Jul 23, 2026 |
| Morgan Stanley | Maintained | Overweight | $120.00 from $100.00 | Jul 23, 2026 |
| Chardan Capital | Maintained | Buy | $115.00 from $90.00 | Jul 22, 2026 |
| JP Morgan | Maintained | Overweight | $95.00 from $88.00 | Jul 17, 2026 |
| Stifel | Initiated Coverage | Buy | $98.00 | Jul 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100.00 | Jul 1, 2026 |
| Chardan Capital | Maintained | Buy | $90.00 | Jun 30, 2026 |
| Leerink Partners | Maintained | Market Perform | $72.00 from $61.00 | Jun 17, 2026 |
| Bernstein | Maintained | Market Perform | $46.00 from $35.00 | May 13, 2026 |
| RBC Capital | Maintained | Outperform | $87.00 from $80.00 | May 8, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $88.00 | May 1, 2026 |
| Morgan Stanley | Upgraded | Equal-Weight → Overweight | $100.00 from $78.00 | Apr 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100.00 | Mar 25, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100.00 | Feb 10, 2026 |
| B. Riley Securities | Maintained | Buy | $101.00 from $61.00 | Jan 22, 2026 |
Frequently asked questions
What is the price target for ARWR stock?
The average 12-month analyst price target for Arrowhead Pharmaceuticals (ARWR) is $107.67, with a high estimate of $126.00 and a low of $72.00, across 9 analysts.
Is ARWR a buy, sell, or hold?
Analysts covering Arrowhead Pharmaceuticals currently average a Buy rating: 14 buy, 0 hold and 0 sell, from 14 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ARWR?
The average price target of $107.67 implies 30.68% upside from the last price of $82.39.
What is the latest analyst rating on ARWR?
On Aug 31, 2026, RBC Capital maintained Arrowhead Pharmaceuticals at Outperform with a price target of $100.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.